Northbrook, IL -- (SBWIRE) -- 12/03/2021 -- According to the new market research report "Flow Cytometry Market by Product (Analyzer, Sorter, Reagents, Consumables, Software), Technology, Application (Research, Clinical - Cancer Diagnostics, Hematology), End User (Academia, Research Labs, Pharma, Biotech, Hospitals) - Global Forecast to 2026", published by MarketsandMarkets™, the market is projected to reach USD 6.3 billion by 2026 from USD 4.3 billion in 2021, at a CAGR of 8.1%.

Browse in-depth TOC on "Flow Cytometry Market"
263 – Tables
40 – Figures
282 – Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=65374584

The Growth in the flow cytometry market is largely driven by the rising global incidence and prevalence of HIV/AIDS and cancer, growing adoption of flow cytometry techniques in research and academia, growing public-private initiatives in the fields of immunology and immuno-oncology research, technological advancements, increasing incorporation of AI platforms in flow cytometry workflows, and increasing advancements in flow cytometry software. However, the high cost of flow cytometry products is a major factor hampering the growth of the market.

The bead-based flow cytometry segment is expected to grow at the highest CAGR during the forecast period

On the basis of technology, the global flow cytometry market is segmented into cell-based and bead-based flow cytometry. The bead-based flow cytometry segment is estimated to witness the highest growth during the forecast period. This technology offers various procedural advantages over other cell-based assays, such as the capacity to detect multiple analytes (also known as multiplexing), high reproducibility, stability, and speed.

Cancer diagnostic segment hold the largest share of the flow cytometry for clinical application market in 2020

In this report, the flow cytometry market for clinical applications is segmented into organ & tissue transplantations, cancer diagnostics, immunodeficiency diseases, hematology, and other clinical applications. Flow cytometry can be applied to cancer studies at every stage by measuring the amount of DNA in cancer cells, analyzing tumor cell proliferation, and immunophenotyping hematological malignancies. In addition, flow cytometry tools are used to determine the malignancy of a tumor by analyzing and enumerating a number of chromosomes and can thus be used to detect cancerous cells.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=65374584

In 2020, the Asia Pacific region accounted for the fasted growing region of the market. The APAC market is expected to offer significant growth opportunities to key market players during the forecast period. Countries in this region are witnessing sustained growth in their GDPs and the disposable incomes of their middle-class population. This is expected to replicate into growth in healthcare spending, research infrastructure modernization, and increased penetration of advanced technologies (including advanced flow cytometry technologies) for research and clinical applications.

The major players operating in the flow cytometry market are Becton, Dickinson and Company (US), Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Luminex Corporation (US), Agilent Technologies, Inc. (US), Sony Group Corporation (Japan), Bio-Rad Laboratories, Inc. (US), Miltenyi Biotec GmbH (Germany), Enzo Biochem, Inc. (US), Sysmex Corporation (Japan), bioMérieux S.A. (France), Cytonome/ ST, LLC (US), Sartorius AG (Germany), Cytek Biosciences, Inc. (US), Union Biometrica, Inc. (US), Apogee Flow Systems Ltd. (UK), Stratedigm, Inc. (US), NanoCellect Biomedical, Inc. (US), On-chip Biotechnologies, Co., Ltd. (Japan), NEXCELOM BIOSCIENCE LLC (US), BennuBio Inc. (US), ORFLO Technologies (US), Bay Biosciences Co., Ltd. (Japan), BioLegend, Inc. (US), and CytoBuoy B.V (Netherlands).

Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=65374584